A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Odanacatib (Primary) ; Calcium; Colecalciferol
- Indications Fracture; Postmenopausal osteoporosis
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms LOFT
- Sponsors Merck Sharp & Dohme
- 01 Oct 2022 Results of post-hoc analysis assessing odanacatib mechanism of action on bone-turnover biomarkers, published in the Osteoporosis International.
- 06 Apr 2022 This trial has been completed in Norway (End Date: 03 Apr 2009), according to European Clinical Trials Database record (EudraCT2009-011920-69).
- 06 Apr 2022 This trial has been completed in Norway (End Date: 03 Apr 2009), according to European Clinical Trials Database record (EudraCT2009-011920-69).